Chuanguang Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chuanguang Xiao has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Han Zhang
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China
1 shared publication- Jun Chu
Department of Nursing, Wuxi Higher Health Vocational Technology School, Wuxi, 2140128, Jiangsu, China
1 shared publication - Kai Wang
Institute of Translational Medicine, Shanghai University, 200444 Shanghai, China
1 shared publication - Liang Li
Department of Breast Thyroid Surgery, Central Hospital of Zibo, Zibo, 255036, Shandong, China
1 shared publication - Lili Lin
Department of Pharmacy, Wuxi Higher Health Vocational Technology School, No. 305, Xinguang Road, Wuxi, 214028, Jiangsu, China
1 shared publication Lizhen Yan
Department of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, 255400 Zibo, Shandong, China
1 shared publication
Latest Publications
- Open Access
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 26721
Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use. Neutrophil cell membrane-derived nanovesicles, with their ability to specifically target hyper-activated immune cells and excellent mucus permeability, emerge as a promising carrier for pulmonary inhalation therapy. Methods: We designed a novel UiO66 metal-organic framework nanoparticle loaded with Dex and coated with neutrophil cell membranes (UiO66-Dex@NMP) for targeted therapy of severe pneumonia. This was achieved by loading Dex into UiO66 pores and subsequently coating with neutrophil membranes for functionalization. Results: Drug release experiments revealed UiO66-Dex@NMP to exhibit favorable sustained-release properties. Additionally, UiO66-Dex@NMP demonstrated excellent targeting capabilities both in vitro and in vivo. In a mouse model of lipopolysaccharide (LPS)-induced pneumonia, UiO66-Dex@NMP significantly reduced lung inflammation compared to both the control model and Dex administered via inhalation. Histopathological analysis further confirmed UiO66-Dex@NMP’s ability to alleviate lung tissue damage. Conclusions: UiO66-Dex@NMP represents a novel and safe inhaled delivery carrier for Dex, offering valuable insights into the clinical management of respiratory diseases, including severe pneumonia.
- 22 January 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (1) , 26721
Open AccessAtomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use. Neutrophil cell membrane-derived nanovesicles, with their ability to specifically target hyper-activated immune cells and excellent mucus permeability, emerge as a promising carrier for pulmonary inhalation therapy. Methods: We designed a novel UiO66 metal-organic framework nanoparticle loaded with Dex and coated with neutrophil cell membranes (UiO66-Dex@NMP) for targeted therapy of severe pneumonia. This was achieved by loading Dex into UiO66 pores and subsequently coating with neutrophil membranes for functionalization. Results: Drug release experiments revealed UiO66-Dex@NMP to exhibit favorable sustained-release properties. Additionally, UiO66-Dex@NMP demonstrated excellent targeting capabilities both in vitro and in vivo. In a mouse model of lipopolysaccharide (LPS)-induced pneumonia, UiO66-Dex@NMP significantly reduced lung inflammation compared to both the control model and Dex administered via inhalation. Histopathological analysis further confirmed UiO66-Dex@NMP’s ability to alleviate lung tissue damage. Conclusions: UiO66-Dex@NMP represents a novel and safe inhaled delivery carrier for Dex, offering valuable insights into the clinical management of respiratory diseases, including severe pneumonia.
- Open Access
- 25 September 2020
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 18 (1) , 1-10
Prognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis
Background: This study intended to determine important genes related to the prognosis and recurrence of breast cancer.Methods: Gene expression data of breast cancer patients were downloaded from TCGA database. Breast cancer samples with recurrence and death were defined as poor disease-free survival (DFS) group, while samples without recurrence and survival beyond 5 years were defined as better DFS group. Another gene expression profile dataset (GSE45725) of breast cancer was downloaded as the validation data. Differentially expressed genes (DEGs) were screened between better and poor DFS groups, which were then performed function enrichment analysis. The DEGs that were enriched in the GO function and KEGG signaling pathway were selected for cox regression analysis and Logit regression (LR) model analysis. Finally, correlation analysis between LR model classification and survival prognosis was analyzed.Results: Based on the breast cancer gene expression profile data in TCGA, 540 DEGs were screened between better DFS and poor DFS groups, including 177 downregulated and 363 upregulated DEGs. A total of 283 DEGs were involved in all GO functions and KEGG signaling pathways. Through LR model screening, 10 important feature DEGs were identified and validated, among which,ABCA3,CCL22,FOXJ1,IL1RN,KCNIP3,MAP2K6, andMRPL13, were significantly expressed in both groups in the two data sets.ABCA3,CCL22,FOXJ1,IL1RN, andMAP2K6were good prognostic factors, whileKCNIP3andMRPL13were poor prognostic factors.Conclusion: ABCA3,CCL22,FOXJ1,IL1RN, andMAP2K6may serve as good prognostic factors, whileKCNIP3andMRPL13may be poor prognostic factors for the prognosis of breast cancer.
- 25 September 2020
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 18 (1) , 1-10
Open AccessPrognostic biomarkers related to breast cancer recurrence identified based on Logit model analysis
Background: This study intended to determine important genes related to the prognosis and recurrence of breast cancer.Methods: Gene expression data of breast cancer patients were downloaded from TCGA database. Breast cancer samples with recurrence and death were defined as poor disease-free survival (DFS) group, while samples without recurrence and survival beyond 5 years were defined as better DFS group. Another gene expression profile dataset (GSE45725) of breast cancer was downloaded as the validation data. Differentially expressed genes (DEGs) were screened between better and poor DFS groups, which were then performed function enrichment analysis. The DEGs that were enriched in the GO function and KEGG signaling pathway were selected for cox regression analysis and Logit regression (LR) model analysis. Finally, correlation analysis between LR model classification and survival prognosis was analyzed.Results: Based on the breast cancer gene expression profile data in TCGA, 540 DEGs were screened between better DFS and poor DFS groups, including 177 downregulated and 363 upregulated DEGs. A total of 283 DEGs were involved in all GO functions and KEGG signaling pathways. Through LR model screening, 10 important feature DEGs were identified and validated, among which,ABCA3,CCL22,FOXJ1,IL1RN,KCNIP3,MAP2K6, andMRPL13, were significantly expressed in both groups in the two data sets.ABCA3,CCL22,FOXJ1,IL1RN, andMAP2K6were good prognostic factors, whileKCNIP3andMRPL13were poor prognostic factors.Conclusion: ABCA3,CCL22,FOXJ1,IL1RN, andMAP2K6may serve as good prognostic factors, whileKCNIP3andMRPL13may be poor prognostic factors for the prognosis of breast cancer.